Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Public ClinicalTrials.gov record NCT05484622. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Safety Lead-In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination With Pembrolizumab in Subjects With Recurrent or Progressive IDH-1 Mutant Glioma
Study identification
- NCT ID
- NCT05484622
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Drug
- Vorasidenib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 19, 2023
- Primary completion
- Feb 11, 2026
- Completion
- Aug 29, 2027
- Last update posted
- Mar 11, 2026
2023 – 2027
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35249 | — |
| University of California, Los Angeles (Site: 840113) | Los Angeles | California | 90095 | — |
| University of California, San Francisco (Site: 840149) | San Francisco | California | 94013 | — |
| University of Colorado | Aurora | Colorado | 80045 | — |
| University of Miami (Site: 840129) | Miami | Florida | 33136 | — |
| Northwestern University (Site: 840123) | Chicago | Illinois | 60045 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital (Site: 840104) | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute (Site: 840139) | Boston | Massachusetts | 02215 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| Memorial Sloan Kettering Cancer Center (Site: 840117) | New York | New York | 10017 | — |
| Duke University (Site: 840110) | Durham | North Carolina | 27705 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Mayo Clinic Florida | Cleveland | Ohio | 44195 | — |
| University of Pennsylvania Health System | Philadelphia | Pennsylvania | 19104 | — |
| MD Anderson Cancer Center (Site: 840102) | Houston | Texas | 77030 | — |
| University of Utah, Huntsman Cancer Center | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05484622, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05484622 live on ClinicalTrials.gov.